Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus

[1]  N. Hahn.  Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study , 2021, Neurology.

[2]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[3]  G. Comi,et al.  Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. , 2020, Multiple sclerosis.

[4]  D. Rizzoni,et al.  Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up , 2020, EClinicalMedicine.

[5]  A. Bar-Or,et al.  Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature , 2020, Nature Reviews Neurology.

[6]  C. Louapre,et al.  Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. , 2020, JAMA neurology.

[7]  M. Filippi,et al.  COVID-19 will change MS care forever – No , 2020, Multiple sclerosis.

[8]  M. Sormani,et al.  Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis , 2020, SSRN Electronic Journal.

[9]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[10]  M. Chiarini,et al.  Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[11]  M. Inglese,et al.  Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[12]  W. Brück,et al.  Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease , 2018, Proceedings of the National Academy of Sciences.

[13]  A. Bar-Or,et al.  Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis , 2018, Neurology.

[14]  X. Montalban,et al.  Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis , 2018, Journal of the Neurological Sciences.

[15]  A. McMichael,et al.  T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.